Advertisement
Screener

GALECTIN THERAPEUTICS INC. (GALT) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

GALECTIN THERAPEUTICS INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount

GALECTIN THERAPEUTICS INC. (GALT) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 51.72 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Income Statement › Earnings Per Share

us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-14

  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 53.82M shares, a 4.86% increase year-over-year.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 51.32M shares, a 23.24% increase year-over-year.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 41.64M shares, a 32.28% increase year-over-year.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 31.48M shares, a 40.77% increase year-over-year.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 52.31M shares, a 6.58% increase from fiscal 2024.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 49.08M shares, a 35.05% increase from fiscal 2023.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 36.34M shares, a 34.78% increase from fiscal 2022.
  • GALECTIN THERAPEUTICS INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 26.96M shares, a 25.54% increase from fiscal 2021.
Period endAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 monthAntidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month
2026-06-3051.72M shares
10-Q · filed 2026-08-14
2026-03-3153.82M shares
10-Q · filed 2026-05-15
2025-12-3152.31M shares
10-K · filed 2026-03-31
2025-09-3049.87M shares
10-Q · filed 2025-11-14
2025-06-3055.19M shares
10-Q · filed 2026-08-14
2025-03-3151.32M shares
10-Q · filed 2026-05-15
2024-12-3149.08M shares
10-K · filed 2026-03-31
2024-09-3049.40M shares
10-Q · filed 2025-11-14
2024-06-3045.44M shares
10-Q · filed 2025-08-14
2024-03-3141.64M shares
10-Q · filed 2025-05-15
2023-12-3136.34M shares
10-K · filed 2025-03-31
2023-09-3033.23M shares
10-Q · filed 2024-11-14
2023-06-3035.04M shares
10-Q · filed 2024-08-13
2023-03-3131.48M shares
10-Q · filed 2024-05-15
2022-12-3126.96M shares
10-K · filed 2024-03-29
2022-09-3023.17M shares
10-Q · filed 2023-11-13
2022-06-3022.52M shares
10-Q · filed 2023-08-14
2022-03-3122.36M shares
10-Q · filed 2023-05-15
2021-12-3121.48M shares
10-K · filed 2023-03-30
2021-09-3019.80M shares
10-Q · filed 2022-11-14
2021-06-3018.84M shares
10-Q · filed 2022-08-15
2021-03-3118.81M shares
10-Q · filed 2022-05-16
2020-12-3117.04M shares
10-K · filed 2022-03-31
2020-09-3017.04M shares
10-Q · filed 2021-11-15
2020-06-3016.79M shares
10-Q · filed 2021-08-16
2020-03-3116.79M shares
10-Q · filed 2021-05-17
2019-12-3116.05M shares
10-K · filed 2021-03-31
2019-09-3016.12M shares
10-Q · filed 2020-11-09
2019-06-3016.12M shares
10-Q · filed 2020-08-10
2019-03-3114.00M shares
10-Q · filed 2020-05-11
2018-12-3117.66M shares
10-K · filed 2020-03-16
2018-09-3018.77M shares
10-Q · filed 2019-11-12
2018-06-3019.42M shares
10-Q · filed 2019-08-09
2018-03-3121.38M shares
10-Q · filed 2019-05-10
2017-12-3122.70M shares
10-K · filed 2019-03-06
2017-09-3021.22M shares
10-Q · filed 2018-11-13
2017-06-3021.22M shares
10-Q · filed 2018-08-14
2017-03-3121.22M shares
10-Q · filed 2018-05-11
2016-12-3122.46M shares
10-K · filed 2018-03-29
2016-09-3017.71M shares
10-Q · filed 2017-11-07
2016-06-3015.27M shares
10-Q · filed 2017-08-14
2016-03-3115.03M shares
10-Q · filed 2017-05-15
2015-12-3114.81M shares
10-K · filed 2017-03-28
2015-09-3011.57M shares
10-Q · filed 2016-11-08
2015-06-3011.43M shares
10-Q · filed 2016-08-09
2015-03-3111.42M shares
10-Q · filed 2016-05-10
2014-12-3111.33M shares
10-K · filed 2016-03-15
2014-09-3011.31M shares
10-Q · filed 2015-11-09
2014-06-3011.30M shares
10-Q · filed 2015-08-10
2014-03-3111.42M shares
10-Q · filed 2015-05-11
2013-12-3111.95M shares
10-K · filed 2016-03-15
2013-09-3012.67M shares
10-Q · filed 2014-11-10
2013-06-3013.57M shares
10-Q · filed 2014-08-07
2013-03-3113.70M shares
10-Q · filed 2014-05-13
2012-12-3113.59M shares
10-K · filed 2015-03-18
2012-09-3013.59M shares
10-Q · filed 2013-11-12
2012-06-3013.34M shares
10-Q · filed 2013-08-14
2012-03-3113.05M shares
10-Q · filed 2013-05-10
2011-12-3112.39M shares
10-K · filed 2013-03-29
2011-09-3012.51M shares
10-Q · filed 2012-11-09
2011-06-3013.01M shares
10-Q · filed 2012-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Rezolute, Inc. (RZLT)United States$0.382B-6.45
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Advertisement